Especially if the TLS are an important contributing factor to the neuropsychiatric manifestations, targeting them by inhibiting certain components, such as CXCL13, or blocking certain functions, is worth pursuing further to develop more effective therapies for lupus and NPSLE. This evidence concerns the gene CXCL13 and systemic lupus erythematosus.